Biology of MDS/MPN overlap syndromes (except CMML)

Slides:



Advertisements
Similar presentations
Spliceosome mutations in myeloid neoplasms
Advertisements

Myelodysplastic syndromes Achievements in understanding and treatment prof. dr hab. med. Krzysztof Lewandowski.
N Engl J Med. 2013 May 9; 368:1781 Speaker: CR 呂學儒醫師
Thrombocytopenia or thrombocytosis? Nancy Rosenthal, MD.
Myelodysplastic Syndromes Austin Kulasekararaj. Background and Why? Described in 1900 Defined as MDS only in 1982-abnormal clone (don’t think it spreads.
GENETICS & biology OF MYELOPROLIFERATIVE NEOPLASMS
Myelodysplastic syndrome overview Razelle Kurzrock Seminars in Haematology, Vol 39, No 3, Suppl 2 (July) 2002, pp
Myelodysplastic syndromes
Prognostication in MF: From CBC to cytogenetics to molecular markers
Genetic changes in MDS.
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
Risk Stratification of Patients with Myelofibrosis and the Role of Transplant Alessandro M. Vannucchi Section of Hematology, University of Florence, Italy.
Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases Presenter: Syed Jawad Noor, PGY3 Mentor: Meir Wetzler June 09, 2010.
Myelodysplastic Syndrome (MDS)
MLAB HEMATOLOGY KERI BROPHY-MARTINEZ Myelodysplastic Syndromes.
Myelodysplastic Syndromes Tefferi A, Vardiman JW. New Engl J Med 2009:361(19):
Pei Lin Professor of Pathology Department of Hematopathology
Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.
Good morning… My presentation is about Calreticulin and PMF
MLAB Hematology Keri Brophy-Martinez
October 2014 Myeloproliferative Neoplasms Angela Fleischman Division of hematology/Oncology.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
골수증식 질환 Myeloproliferative disorders (MPD) [ 새로운 분류와 진단 기준 ] 경희의대 종양혈액내과 조 경 삼.
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
Case 324 SH/EAH Workshop - Huston TX, October 2013 Leonardo Boiocchi, M.D. & Attilio Orazi, M.D. Weil Cornell Medical College, New York, NY Università.
CASE 411 Jose Gonzalez-Berjon, MD & Tariq Muzzafar, MD UT M.D. Anderson Cancer Center.
Session 7, case 171 Extramedullary Manifestations of Myeloid Neoplasms
Myelodysplastic Syndromes
Myelodysplastic syndrome(MDS)
  PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE LOCI OF GENE VARIANCES PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE.
Acute Myeloid Leukemia
Julia Geyer and Attilio Orazi
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
New Findings in Hematology: Independent Conference Coverage
Sekeres MA et al. Proc ASH 2015;Abstract 908.
MLAB Hematology Keri Brophy-Martinez
Clearance of ‘Driver-COSMIC’ mutations post-CR1 with persisting RUNX1_L56S is unlikely to contribute towards disease progression L . Rai1, T. Boneva1,
5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) as Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)1  
NGS tests and algorithms in (hemato)-oncology ComPerMed
Verstovsek S et al. Proc ASH 2011;Abstract 793.
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis New Findings in Hematology: Independent Conference Coverage.
New Molecular Abnormalities Recognized in AML
New Findings in Hematology: Independent Conference Coverage
HS 4160 Critical Scientific Analysis
Program Goals Case 1: Woman With MDS Risk: Cytogenetic Subgroups.
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Fenaux P et al. Lancet Oncol 2009;10(3):
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
Whom should you refer for allogeneic stem cell transplantation?
Which mutations matter in myelofibrosis?
European Focus on MPN and MDS 2014
by Mario Cazzola, Marianna Rossi, and Luca Malcovati
Myelodysplastic Syndromes
The genetic basis of myelodysplasia and its clinical relevance
by R. Coleman Lindsley, and Benjamin L. Ebert
Prefibrotisk Myelofibros
Myelodysplastic syndromes
MYELODYSPLASTIC SYNDROME: prognosis & treatment options
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Lingering Uncertainties and Emerging Possibilities  Sudipto Mukherjee, Dominic.
Hematology Journal Club
Pathogenesis of myeloproliferative neoplasms
Acute Leukemia Dr. Noha Noufal.
In the name of god.
Chronic Leukemia Dr. Noha Noufal.
by Ayalew Tefferi, Terra L. Lasho, Paola Guglielmelli, Christy M
ASH Review 2018: Update on Myelodysplastic Syndrome
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
Kantarjian HM et al. Blood 2008;112:Abstract 635.
by Elisa Rumi, and Mario Cazzola
Presentation transcript:

Biology of MDS/MPN overlap syndromes (except CMML) Andreas Reiter Haematology and Oncology University Medical Center Mannheim Ruprecht-Karls-University Heidelberg Germany

WHO 2008: Myeloid Neoplasms AML MDS Myeloid neoplasms MDS/MPN MPN MLN-eo aCML CML PMF CEL PDGFRA MDS/MPNu PV CNL MCD PDGFRB ( RARS-T ) ET MPNu FGFR1 CMML JMML

Diagnostic algorithm of MDS/MPN WBC >13x109/l or platelets >450x109/l At least one cytopenia: Hb <13/<12g/dl (m/f) Platelets <140x109/l WBC <1.8x109/l Dysplasia >10% in at least one lineage MDS/MPN Platelets >450x109/l Anemia and >15% ring sideroblasts WBC >13x109/l Dysplastic granulopoiesis >10% Myeloid precursors >10% RARS-T Atypical CML Monocytosis >1x109/l (and >10%) Dysplasia in at least one lineage or Cytogenetic or molecular aberration CMML

Median survival (months) Survival in MDS/MPN Median survival (months) aCML 25 (22-77) RARS-T 46 (39-82) MDS/MPNu <5% blasts >5% blasts 20 31 8 CMML CMML-1 CMML-2 14 (10-32) 19 13 Orazi A and Germing U, Leukemia, 2008 Breccia et al, Haematologica, 2006 Sekeres M, ASCO Annual Meeting, 2013

AML-free and overall survival in atypical CML and MDS/MPNu  Wang et al, Blood, in press

MDS/MPN-U: natural history and clinical outcome by treatment strategy MDS/MPN-U without RARS-T (n=85) Median age 70 years (22-90), 90% >60 years JAK2 V617F positive (17/56, 30%) No treatment regimen significantly improved response Hypomethylating agents (n=36, 42%) Immunomodulatory drugs (n=13, 15%) Allogeneic stem cell transplant (n=5, 6%) Median OS 12.4 months (0.3–138.7) MDS-IPSS and MDA global score provided statistical significance in univariate analysis, only thrombocytosis (52.5 vs. 11.9 months, p<0.001) was prognostic in multivariate analysis Ongoing clinical trial incorporating the combination of ruxolitinib and azacitidine DiNardo et al., Leukemia 28, 961-4, 2014

Mutations and prognosis in RARS/RARS-T JAK2 V617F mutation ~60% SF3B1 mutation >80% MPL W515 mutation ~ 5% High-risk: Age >80 years SF3B1 wt JAK2 wt Broséus et al, Leukemia 2013

Molecular genetics of RARS/RARS-T Somatic mutation SF3B1 (60-80%): mitochondrial iron overload, ineffective erythropoiesis, anemia Somatic mutation in JAK2 or MPL (70-80%): thrombocytosis Hematopoietic stem cell Ring sideroblasts and ineffective erythropoiesis (myelodysplastic features of RARS) Ring sideroblasts and thrombocytosis (myelodysplastic & myeloproliferative features of RARS-T) Cazzola et al. Blood 121, 260-9, 2013 8

Molecular genetics of atypical CML SETBP1 mutations in ≈25% of aCML SETBP1 Piazza R et al, Nat Genetics, 2013 Makishima H et al, Nat Genetics, 2013

SETBP1 mutation in atypical CML WBC (p=0.008) Hb (p=0.44) Platelets (p=0.16) SETBP1- = 77 months SETBP1+ = 22 months p=0.01, HR=2,27 Piazza et al, Nat Genetics, 2013

Diagnostic algorithm of MDS/MPN WBC >13x109/l or platelets >450x109/l At least one cytopenia: Hb <13/<12g/dl (m/f) Platelets <140x109/l WBC <1.8x109/l Dysplasia >10% in at least one lineage WBC >25x109/l Mature neutrophils and bands Leukocytes appear toxic No precursors No dysgranulopoiesis MDS/MPN CNL Platelets >450x109/l Anemia and >15% ring sideroblasts WBC >13x109/l Dysplastic granulopoiesis >10% Myeloid precursors >10% RARS-T Atypical CML Monocytosis >1x109/l (and >10%) Dysplasia in at least one lineage or Cytogenetic or molecular aberration CMML

aCML vs. CNL aCML CNL

Molecular characteristics of aCML and CNL CSF3R SETBP1 Reference CNL aCML Maxson et al, NEJM, 2013; Gotlib et al, Blood, 2013 8/9 (89%) 8/20 (40%) 5/9 (56%) 3/20 (15%) Pardanani et al, Leukemia, 2013 10/12 (83%) 0/19 (0%) 4/12 (33%) Meggendorfer et al, ASH 2013 7/20 (35%) 2/60 (3%) 2/19 (11%) 19/60 (32%) Piazza et al, ASH 2013 N/A 8/65 (12%) 18/65 (28%) Piazza et al, Nature Genetics, 2013 17/70 (24%) Courtesy of J. Gotlib

Molecular characteristics of aCML and CNL ASXL1 SETBP1 CSF3R SRSF2 aCML 64% 32% 3% 40% CNL 73% 11% 35% 21% CMML 44% 5% 1% 48% Meggendorfer et al., Abstract 105, ASH 2013

MDS/MPN with CBL mutations % Myeloproliferative features Leukocytosis (>10x109/l) 11/13 85% Myeloid precursors >10% 12/13 92% Increased BM cellularity 11/12 BM fibrosis (no grade III) 10/13 77% Splenomegaly Myelodysplastic features Anemia (<13g/dl) 13/13 100% Thrombocytopenia (<150x109/l) 8/13 62% Monocytosis (>1x109/l) Dysplasia in BM and PB 10/12 83% Prior diagnosis (n=13) CMML (n=6) MDS/MPNu (n=4) aCML (n=2) PMF (n=1) 5 patients positive for mutations in EZH2 (n=3) and TET2 (n=2) Allogeneic SCT (n=2) Three-year survival rate was 27% Schwaab et al., Annals of Haematology 91; 2012: 1713

No abnormality defines specific disease entities except BCR-ABL Classes of somatically acquired driver mutation in MPN, MDS/MPN and MDS SIGNAL-LING EPIGE-NETIC mRNA SPLICING TRAN-SCRIPTION COHESIN CYTO TK fusions JAK2 MPL CBL NF1 NRAS KRAS CSF3R RIT1 PTPN11 FLT3 KIT SETBP1 CALR TET2 DNMT3A IDH1/2 EZH2 ASXL1 PHF6 CREBP EP300 SF3B1 SRSF2 U2AF1 ZRSR2 LUC7L2 PPRF8 RUNX1 TP53 ETV6 BCOR CUX1 STAG2 SMC1A SMC3 RAD21 5q- -7/7q +8 +19 i(17q) del(11q) del(12p) del(20q) inv(3q) t(3;3) No abnormality defines specific disease entities except BCR-ABL

Molecular heterogeneity in MDS/MPN and MPN Molecular aberrations initiating modifying transforming cooperating no functional role RAS RUNX1 TP53 ... Genetic predisposition Genotype in mice Familial MPN Haplotype 46/1 JAK2 V617F JAK2 exon 12 CALR MPL KIT D816V Phenotype Progression SF3B1 SETBP1 SRSF2 ASXL1 CSF3R TET2 EZH2 ...

Biology of MDS/MPN: conclusion Diagnosis Challenging Overlap of morphologic findings Pathogenesis Mutations in various genes Molecular heterogeneity Some of them rather disease-specific Prognostic relevance Prognosis Poor Thrombocytosis is a favourable risk factor Increasing importance of the mutational profile Treatment No targeted treatment Allogeneic SCT is rarely performed Current strategies do not affect progression or survival